摘要
目的：探讨重组人干扰素α-1b雾化治疗儿童呼吸道病毒感染性疾病的临床疗效及安全性。方法采用随机、对照的临床试验设计，将375例儿童呼吸道病毒感染性疾病患儿分为治疗组250例和对照组125例，除常规治疗外，治疗组加用重组人干扰素α-1b雾化治疗，对照组加用利巴韦林雾化治疗。结果共有357例纳入统计，治疗组发热、咽痛、咳嗽、喘憋、肺部啰音消失时间及住院时间均优于对照组（ u＝5．83、6．51、6．33、7．39、5．57、6．62，均P＜0．01）；治疗组治愈率及总有效率分别为40．83％、82．92％，明显高于对照组的25．64％、58．12％（χ2＝7．85、25．71，均P＜0．01）；两组均未见明显不良反应。结论重组人干扰素α-1b雾化治疗儿童呼吸道病毒感染性疾病安全有效，方法简单，值得临床推广。
Objective To investigate the clinical efficacy and safety of nebulization treatment for childhood respiratory virus infection with human recombinant interferon α-1b.Methods A randomized,controlled clinical re-search was designed.375 subjects with children respiratory tract virus infection were randomly divided into the treat-ment group（250 cases） and control group（125 cases）.In addition to conventional therapy,the treatment group with recombinant human interferon α-1b and the control group with ribavirin were executed by using nebulization treat-ment.Results A total of 357 subjects were statistically included in the trail.Sore throat,cough,wheezes,rale of lung disappearing time and the days of hospitalization of treatment group were significantly different（u=5.83,6.51,6.33, 7.39,5.57,6.62,all P〈0.01） compared with the control group;The treatment group in the cure rate and total effec-tive rate was significantly higher（χ2 =7.85,25.71,all P〈0.01）,and no obvious adverse reactions were reported. Conclusion Nebulization treatment of childhood respiratory virus infection with human recombinant interferon α-1b is safe and effective.The method of operation is simple and thus its application is worth promoting in clinic.
出处
《中国基层医药》
CAS
2014年第21期3207-3209,共3页
Chinese Journal of Primary Medicine and Pharmacy
基金
河南省卫生厅科研项目基金（201203111）
